ReviewPorto biomedical journal
Autoimmune thyroid disease in infertility and assisted reproductive technology: A review.
Review in Porto biomedical journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Autoimmune thyroiditis in pregnancy: epidemiology, clinical impact, and contemporary management challenges.Journal of medicine and life · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune thyroid disease (ATD), implicated in infertility and unfavorable outcomes in assisted reproductive technology (ART), is the most prevalent autoimmune disorder among women of reproductive age. This review summarizes the existing evidence on the impact of ATD on infertility and ART outcomes, with a particular focus on screening and therapeutic options. Subclinical hypothyroidism (SCH) frequently coexists with ATD. Thyroid-stimulating hormone (TSH) thresholds for SCH treatment in fertility range from 2.5 to 4.0 mIU/L, causing inconsistencies in clinical management. Although levothyroxine is widely recommended for TSH >4.0 mIU/L, benefits for lower thresholds remain controversial. Immunomodulatory therapies, such as glucocorticoids and intravenous immunoglobulin, have uncertain efficacy in improving ART outcomes. This review highlights the pressing need for standardized diagnostic criteria and therapeutic interventions to optimize fertility outcomes in ATD-positive women, particularly with SCH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.